DocWire News Editors

DocwireNews

Real-world data showed a high unmet medical need among older patients with diffuse large B-cell lymphoma (DLBCL): Up to 35% of patients were receiving no treatment, and more than 50% were receiving attenuated treatment, according to a study presented at the 2020 ASH Annual Meeting.
“These data show a high unmet medical need among elderly patients with DLBCL who may not be able to tolerate immunochemotherapy regimens that have been evaluated in trials for a carefully selected patient population,” the researchers noted.
Researchers used real-world data from the Flatiron Health (FH) electronic health record (EHR)-derived deidentified database and Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Data from the FH EHRs included 725 patients with a DLBCL diagnosis on or after January 1, 2011, who had follow-up through May 31, 2020. The SEER-Medicare database included 2,613 patients with a DLBCL diagnosis between January 1, 2011, and December 31, 2015, who had follow-up through December 31, 2016. Researchers included patients who were aged ≥80 years at diagnosis.
Among patients in the FH database who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy and had available dosing data, those who received &lt;80% of standard full doses for cyclophosphamide 750mg/m2 and doxorubicin 50mg/m2 at first administration were classified as “reduced-dose” R-CHOP.
In the FH dataset, 117 patients were untreated, as were 915 in the SEER-Medicare dataset. More than half of the treated patients received R-CHOP in the first line of therapy (63% in the FH database and 53% in the SEER-Medicare database); other patients received attenuated regimens, including rituximab plus bendamustine; rituximab plus cyclophosphamide, vincristine, and prednisolone; and rituximab monotherapy.
Patients who received R-CHOP in the first line of therapy had numerically longer median overall survival (FH, 55.0 months [95% confidence interval [CI], 41.8 to not available]; SEER-Medicare, 50.7 months [95% CI, 45.9-62.9]) compared with those who received other regimens. Untreated patients had a median survival of 3.1 months (95% CI, 2.3-5.2) in the FH dataset and 2.0 months (95% CI, 1.8-2.2) in the SEER-Medicare dataset.
Among those who received R-CHOP and had available dosing data, 51% received reduced-dose R-CHOP in the first line of therapy, and overall survival appeared shorter than for patients who received full-dose R-CHOP.
Reference
Shewade A, Olszewski AJ, Pace N, et al. Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States. Abstract 1202. Presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition, December 2-11, 2020.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Real-World Data Show Considerable Variation in DLBCL Regimens for Older Patients

ASH Annual Meeting 2020

Real-world data showed a high unmet medical need among older patients with diffuse large B-cell lymphoma (DLBCL): Up to 35% of patients were receiving no treatment, and more ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe